

OFFICE & SHIPPING ADDRESS:Ob dem Himmelreich 7
72074 Tuebingen
GermanyPOSTAL ADDRESS:Postfach 2204
72012 Tuebingen
GermanyEMAIL:

info@panatecs.com

DATA SHEET - CEF-Peptide-Pool

Catalog No.:	PA-CEF-001
Product:	CEF – Peptide – Pool
Formulation:	Lyophilized
Description:	<p>This pool contains 23 HLA class I-restricted T-cell epitopes from human Cytomegalovirus, Epstein-Barr virus and Influenza virus.</p> <p>The CEF-Pool stimulates the release of IFN-gamma from CD8⁺ T-cells in individuals with certain highly frequent HLA types (HLA: A1, A2, A3, A11, A24, A68, B7, B8, B27, B35, B44). The CEF Peptide Pool ist useful as a peptide-specific positive control in ELISPOT, CTL and Intracellular Cytokine Assays using human PBMC.</p>
Recommended test concentration:	<p>For Elispot we recommend the following usage: 2µg of each peptide/ml with a final volume of 100µl/well (0.2µg of each peptide/well).</p> <p>For other T cellular assays (e.g. cytokine flow cytometry) the optimum conditions should be tested by the customer.</p>
Short-time Storage:	+4 °C
Long-time Storage:	-20°C
Dissolving:	Add 1ml of cell culture medium (e.g. RPMI 1640) per vial. Dissolve the peptide pool by vortexing three times for 1 minute (stock solution).
Working solution:	Dilute the stock solution (20µg of each Peptide/ml) 1:5 with cell culture medium to a concentration of 4µg of each peptide/ml.
Aliquotation:	Freeze 50µl Aliquots (-20 °C). One 50µl aliquot is sufficient to analyze 1 ELISPOT sample.
Containing Peptides:	VSDGGPNLY (Influenza A, HLA-A1), CTELKLSDY (Influenza A, HLA-A1), GILGFVFTL (Influenza A, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2), KTG GPIYKR (Influenza A, HLA-A68), ILRGSVAHK (Influenza A, HLA-A3), RVRAYTYSK (EBV, HLA-A3), RLRAEQVK (EBV, HLA-A3), IVTDFSVIK (EBV, HLA-A11), ATIGTAMYK (EBV, HLA-A11), DYC NVLNKEF (EBV, HLA-A24), RPPIFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8), OAKWRLQTL (EBV, HLA-B8), SRYWAI RTR (Influenza A, HLA-B27), RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), EENLLDFVRF (EBV, HLA-B44), EFFWDANDIY (HCMV, HLA-B44), TPRVTGGGAM (HCMV, HLA-B7).
References:	Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260:157-172, 2002.
Attention:	For research use only, not for diagnostic use! Not for use in humans.